NCT05451420View on ClinicalTrials.gov

Inactive HBsAg Carriers (IHCs) Treated With Pegylated Interferon α2b Based Intervention Therapy

NACompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 1, 2017

Primary Completion Date

June 30, 2020

Study Completion Date

December 31, 2021

Conditions

Chronic Hepatitis B

Interventions

DRUG

PegIFN α- 2b

"Adjuvant immunotherapy with GM-CSF and Hepatitis B vaccine~；GM-CSF（100 μg/ piece, produced by Xiamen Tebao Bioengineering Co., Ltd）；Hepatitis B vaccine（Each 1.0ml/HBsAg60 μ g. Shenzhen Kangtai Biological Products Co., Ltd）"

Trial Locations (1)

450000

Henan Provincial People's Hospital, Zhengzhou

All Listed Sponsors

collaborator

Xiamen Amoytop Biotech Co., Ltd.

INDUSTRY

lead

Henan Provincial People's Hospital

OTHER

NCT05451420 - Inactive HBsAg Carriers (IHCs) Treated With Pegylated Interferon α2b Based Intervention Therapy | Biotech Hunter | Biotech Hunter